



IFW

Patent
Attorney Docket No. 1017753-000200

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
Manuel ROSA-CALATRAVA et al.) Group Art Unit: 1632
Application No.: 10/520,626) Examiner: Unassigned
Filed: January 10, 2005) Confirmation No.: 9366
For: MODIFIED ADENOVIRAL FIBER)
WITH ABLATED TO CELLULAR)
RECEPTORS)

TRANSMITTAL LETTER FOR NOTICE TO COMPLY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In complete response to the Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated October 10, 2006, enclosed please find:

- a Combined Declaration and Power of Attorney signed by the inventor(s);
- Note that the inventor identified on the concurrently filed Combined Declaration and Power of Attorney is different than listed on the application filing papers.
<<OR>> Note that the inventors identified on the currently filed Combined Declaration and Power of Attorney are different than listed on the application papers.
- an Application Data Sheet <<OR>> a Supplemental Application Data Sheet;
- the surcharge of \$ 65.00 \$ 130.00 as set forth in 37 C.F.R. § 1.16(e);
- a Request for Refund;
- a Petition for Extension of Time;
- a verified English translation of the application, and the 130 fee as set forth in 37 C.F.R. § 1.17(k);
- drawings for publication;
- an Information Disclosure Statement;
- a certified copy of the priority document <<OR>> certified copies of the priority documents;

Transmittal Letter for Missing Parts of Application

Application No.. 10/520,626

Attorney Docket No. 1017753-000200

Page 2

- copy of Notice to Comply; and
- Response to Notice Under 37 CFR 1.821-825
- Small entity status is hereby claimed.
- Charge _____ to Deposit Account No. 02-4800 for the fee due.
- A check in the amount of _____ is enclosed for the fee due.
- Charge _____ to credit card for the fee due. Form PTO-2038 is attached.
- The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date December 7, 2006

By:


Deborah H. Yellin
Registration No. 45,904

P.O. Box 1404
Alexandria, VA 22313-1404
703 836 6620



UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/520,626	Manuel Rosa-Calatrava	017753-200
INTERNATIONAL APPLICATION NO.		
PCT/IB03/03336		
I.A. FILING DATE	PRIORITY DATE	
07/10/2003	07/10/2002	
CONFIRMATION NO. 9366		
371 FORMALITIES LETTER		
 OC000000020686295		

Date Mailed: 10/10/2006

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- The paper or compact disc copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e). Applicant must provide a substitute paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application OR a substitute computer readable form (CRF) copy of the "Sequence Listing". These two items must be the same. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

A copy of this notice MUST be returned with the response.

DONNA S GREENE

Telephone: (703) 308-9140 EXT 222

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/520,626	PCT/IB03/03336	017753-200

FORM PCT/DO/EO/922 (371 Formalities Notice)